421 related articles for article (PubMed ID: 17389511)
1. Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes.
Inan UU; Avci B; Kusbeci T; Kaderli B; Avci R; Temel SG
Invest Ophthalmol Vis Sci; 2007 Apr; 48(4):1773-81. PubMed ID: 17389511
[TBL] [Abstract][Full Text] [Related]
2. Testing toxicity of multiple intravitreal injections of bevacizumab in rabbit eyes.
Xu W; Wang H; Wang F; Jiang Y; Zhang X; Wang W; Qian J; Xu X; Sun X
Can J Ophthalmol; 2010 Aug; 45(4):386-92. PubMed ID: 20648082
[TBL] [Abstract][Full Text] [Related]
3. Safety of intravitreal bevacizumab in the developing rabbit retina.
Zayit-Soudry S; Zemel E; Barak A; Perlman I; Loewenstein A
Retina; 2011 Oct; 31(9):1885-95. PubMed ID: 21799464
[TBL] [Abstract][Full Text] [Related]
4. Effect of intravitreal injection of high-dose bevacizumab in monkey eyes.
Sakurai K; Akiyama H; Shimoda Y; Yoshida I; Kurabayashi M; Kishi S
Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4905-16. PubMed ID: 19407010
[TBL] [Abstract][Full Text] [Related]
5. Safety of intravitreal injection of bevacizumab in rabbit eyes.
Feiner L; Barr EE; Shui YB; Holekamp NM; Brantley MA
Retina; 2006 Oct; 26(8):882-8. PubMed ID: 17031287
[TBL] [Abstract][Full Text] [Related]
6. Effects of intravitreal bevacizumab in repeated doses: an experimental study.
Sari A; Adiguzel U; Canacankatan N; Yilmaz N; Dinc E; Oz O
Retina; 2009 Oct; 29(9):1346-55. PubMed ID: 19934825
[TBL] [Abstract][Full Text] [Related]
7. Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model.
Bakri SJ; Cameron JD; McCannel CA; Pulido JS; Marler RJ
Am J Ophthalmol; 2006 Jul; 142(1):162-4. PubMed ID: 16815270
[TBL] [Abstract][Full Text] [Related]
8. Long-term tolerability and serum concentration of bevacizumab (avastin) when injected in newborn rabbit eyes.
Wu WC; Lai CC; Chen KJ; Chen TL; Wang NK; Hwang YS; Yeung L; Li LM
Invest Ophthalmol Vis Sci; 2010 Jul; 51(7):3701-8. PubMed ID: 20181842
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab (avastin) does not harm retinal function after intravitreal injection as shown by electroretinography in adult mice.
Heiduschka P; Julien S; Hofmeister S; Bartz-Schmidt KU; Schraermeyer U
Retina; 2008 Jan; 28(1):46-55. PubMed ID: 18185137
[TBL] [Abstract][Full Text] [Related]
10. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin).
Shahar J; Avery RL; Heilweil G; Barak A; Zemel E; Lewis GP; Johnson PT; Fisher SK; Perlman I; Loewenstein A
Retina; 2006 Mar; 26(3):262-9. PubMed ID: 16508424
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effect of intravitreal injection of bevacizumab on nerve growth factor.
Jee D; Lee WK
Curr Eye Res; 2012 May; 37(5):408-15. PubMed ID: 22040304
[TBL] [Abstract][Full Text] [Related]
12. Comparative evaluation of apoptotic activity in photoreceptor cells after intravitreal injection of bevacizumab and pegaptanib sodium in rabbits.
Avci B; Avci R; Inan UU; Kaderli B
Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3438-46. PubMed ID: 19255151
[TBL] [Abstract][Full Text] [Related]
13. Penetration of bevacizumab through the retina after intravitreal injection in the monkey.
Heiduschka P; Fietz H; Hofmeister S; Schultheiss S; Mack AF; Peters S; Ziemssen F; Niggemann B; Julien S; Bartz-Schmidt KU; Schraermeyer U;
Invest Ophthalmol Vis Sci; 2007 Jun; 48(6):2814-23. PubMed ID: 17525217
[TBL] [Abstract][Full Text] [Related]
14. Clinical factors related to recurrence of anterior segment neovascularization after treatment including intravitreal bevacizumab.
Saito Y; Higashide T; Takeda H; Murotani E; Ohkubo S; Sugiyama K
Am J Ophthalmol; 2010 Jun; 149(6):964-972.e1. PubMed ID: 20381786
[TBL] [Abstract][Full Text] [Related]
15. Clinical and histological findings after intravitreal injection of bevacizumab (Avastin) in a porcine model of choroidal neovascularization.
Lassota N; Prause JU; Scherfig E; Kiilgaard JF; la Cour M
Acta Ophthalmol; 2010 May; 88(3):300-8. PubMed ID: 19416113
[TBL] [Abstract][Full Text] [Related]
16. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.
Arimura N; Otsuka H; Yamakiri K; Sonoda Y; Nakao S; Noda Y; Hashiguchi T; Maruyama I; Sakamoto T
Ophthalmology; 2009 May; 116(5):921-6. PubMed ID: 19410951
[TBL] [Abstract][Full Text] [Related]
17. Infliximab exerts a dose-dependent effect on retinal safety in the albino rabbit.
Zayit-Soudry S; Vainer I; Zemel E; Mimouni M; Rabena M; Pieramici DJ; Perlman I; Loewenstein A
Doc Ophthalmol; 2017 Dec; 135(3):175-185. PubMed ID: 28825191
[TBL] [Abstract][Full Text] [Related]
18. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab.
Peters S; Heiduschka P; Julien S; Ziemssen F; Fietz H; Bartz-Schmidt KU; ; Schraermeyer U
Am J Ophthalmol; 2007 Jun; 143(6):995-1002. PubMed ID: 17449002
[TBL] [Abstract][Full Text] [Related]
19. Retinal toxicity of commercially available intravitreal ketorolac in albino rabbits.
Komarowska I; Heilweil G; Rosenfeld PJ; Perlman I; Loewenstein A
Retina; 2009 Jan; 29(1):98-105. PubMed ID: 18626418
[TBL] [Abstract][Full Text] [Related]
20. Retinal function and morphology in rabbit after intravitreal injection of VEGF inhibitors.
Myers AC; Lövestam Adrian M; Bruun A; Ghosh F; Andréasson S; Ponjavic V
Curr Eye Res; 2012 May; 37(5):399-407. PubMed ID: 22510009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
